Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women

Monika Sarkar, Jennifer L. Dodge, Ruth M. Greenblatt, Mark H. Kuniholm, Jack Dehovitz, Michael Plankey, Andrea Kovacs, Audrey L. French, Eric C. Seaberg, Igho Ofotokun, Margaret A Fischl, Edgar Overton, Erin Kelly, Peter Bacchetti, Marion G. Peters

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Severity of hepatic fibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects of estrogens. However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in coinfected populations. Methods. In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progression across reproductive age, using validated serum fibrosis markers, aminotransferase platelet ratio index (APRI) and fibrosis 4 (FIB-4). Fibrosis rate was evaluated within each woman as she transitioned from pre- to postmenopause, defined by a biomarker of ovarian function. Results. The median follow-up (n = 405) was 9.1 years (interquartile range, 5.0-15.2 years), with a median menopausal age of 49 years (47-52 years). When fully controlled for chronologic aging, the fibrosis progression rate was accelerated during perimenopause, as shown using FIB-4 (0.12 units per year faster than during premenopause; 95% confidence interval [CI], .02-.21; P = .01) and APRI (0.05 units per year faster; ?.002 to .09; P = .06). Accelerated fibrosis was also observed during postmenopause compared with premenopause, for FIB-4 (0.14 units per year faster; 95% CI, ?.01 to .29; P = .07) and APRI (0.07 units per year faster; ?.003 to .15; P = .06). Accelerated fibrosis in perimenopause persisted after adjustment for Hispanic ethnicity, antiretroviral use, and alcohol (0.10 FIB-4 units per year faster than during premenopause; 95% CI, .008-.20; P = .03). Conclusions. In HIV/HCV-coinfected women, hepatic fibrosis accelerates with reproductive aging. Accelerated fibrosis begins in perimenopause, highlighting a previously unrecognized group of women at increased risk for advanced fibrosis and associated complications. Longitudinal analyses of fibrosis rates across reproductive age should be conducted in non-HCV-related liver diseases, given potential implications in a broader spectrum of women.

Original languageEnglish (US)
Pages (from-to)1695-1702
Number of pages8
JournalClinical Infectious Diseases
Volume65
Issue number10
DOIs
StatePublished - Nov 15 2017

Fingerprint

Hepacivirus
Fibrosis
HIV
Liver
Premenopause
Perimenopause
Transaminases
Postmenopause
Blood Platelets
Confidence Intervals
Estrogens
Biomarkers
Hispanic Americans
Liver Cirrhosis
Liver Diseases

Keywords

  • anti-mllerian hormone
  • fibrosis markers
  • hepatic scarring
  • hormones
  • menopause

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Sarkar, M., Dodge, J. L., Greenblatt, R. M., Kuniholm, M. H., Dehovitz, J., Plankey, M., ... Peters, M. G. (2017). Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. Clinical Infectious Diseases, 65(10), 1695-1702. https://doi.org/10.1093/cid/cix643

Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. / Sarkar, Monika; Dodge, Jennifer L.; Greenblatt, Ruth M.; Kuniholm, Mark H.; Dehovitz, Jack; Plankey, Michael; Kovacs, Andrea; French, Audrey L.; Seaberg, Eric C.; Ofotokun, Igho; Fischl, Margaret A; Overton, Edgar; Kelly, Erin; Bacchetti, Peter; Peters, Marion G.

In: Clinical Infectious Diseases, Vol. 65, No. 10, 15.11.2017, p. 1695-1702.

Research output: Contribution to journalArticle

Sarkar, M, Dodge, JL, Greenblatt, RM, Kuniholm, MH, Dehovitz, J, Plankey, M, Kovacs, A, French, AL, Seaberg, EC, Ofotokun, I, Fischl, MA, Overton, E, Kelly, E, Bacchetti, P & Peters, MG 2017, 'Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women', Clinical Infectious Diseases, vol. 65, no. 10, pp. 1695-1702. https://doi.org/10.1093/cid/cix643
Sarkar, Monika ; Dodge, Jennifer L. ; Greenblatt, Ruth M. ; Kuniholm, Mark H. ; Dehovitz, Jack ; Plankey, Michael ; Kovacs, Andrea ; French, Audrey L. ; Seaberg, Eric C. ; Ofotokun, Igho ; Fischl, Margaret A ; Overton, Edgar ; Kelly, Erin ; Bacchetti, Peter ; Peters, Marion G. / Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. In: Clinical Infectious Diseases. 2017 ; Vol. 65, No. 10. pp. 1695-1702.
@article{332a3cfeaf1e43a6a104956cfa71547f,
title = "Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women",
abstract = "Background. Severity of hepatic fibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects of estrogens. However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in coinfected populations. Methods. In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progression across reproductive age, using validated serum fibrosis markers, aminotransferase platelet ratio index (APRI) and fibrosis 4 (FIB-4). Fibrosis rate was evaluated within each woman as she transitioned from pre- to postmenopause, defined by a biomarker of ovarian function. Results. The median follow-up (n = 405) was 9.1 years (interquartile range, 5.0-15.2 years), with a median menopausal age of 49 years (47-52 years). When fully controlled for chronologic aging, the fibrosis progression rate was accelerated during perimenopause, as shown using FIB-4 (0.12 units per year faster than during premenopause; 95{\%} confidence interval [CI], .02-.21; P = .01) and APRI (0.05 units per year faster; ?.002 to .09; P = .06). Accelerated fibrosis was also observed during postmenopause compared with premenopause, for FIB-4 (0.14 units per year faster; 95{\%} CI, ?.01 to .29; P = .07) and APRI (0.07 units per year faster; ?.003 to .15; P = .06). Accelerated fibrosis in perimenopause persisted after adjustment for Hispanic ethnicity, antiretroviral use, and alcohol (0.10 FIB-4 units per year faster than during premenopause; 95{\%} CI, .008-.20; P = .03). Conclusions. In HIV/HCV-coinfected women, hepatic fibrosis accelerates with reproductive aging. Accelerated fibrosis begins in perimenopause, highlighting a previously unrecognized group of women at increased risk for advanced fibrosis and associated complications. Longitudinal analyses of fibrosis rates across reproductive age should be conducted in non-HCV-related liver diseases, given potential implications in a broader spectrum of women.",
keywords = "anti-mllerian hormone, fibrosis markers, hepatic scarring, hormones, menopause",
author = "Monika Sarkar and Dodge, {Jennifer L.} and Greenblatt, {Ruth M.} and Kuniholm, {Mark H.} and Jack Dehovitz and Michael Plankey and Andrea Kovacs and French, {Audrey L.} and Seaberg, {Eric C.} and Igho Ofotokun and Fischl, {Margaret A} and Edgar Overton and Erin Kelly and Peter Bacchetti and Peters, {Marion G.}",
year = "2017",
month = "11",
day = "15",
doi = "10.1093/cid/cix643",
language = "English (US)",
volume = "65",
pages = "1695--1702",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women

AU - Sarkar, Monika

AU - Dodge, Jennifer L.

AU - Greenblatt, Ruth M.

AU - Kuniholm, Mark H.

AU - Dehovitz, Jack

AU - Plankey, Michael

AU - Kovacs, Andrea

AU - French, Audrey L.

AU - Seaberg, Eric C.

AU - Ofotokun, Igho

AU - Fischl, Margaret A

AU - Overton, Edgar

AU - Kelly, Erin

AU - Bacchetti, Peter

AU - Peters, Marion G.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Background. Severity of hepatic fibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects of estrogens. However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in coinfected populations. Methods. In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progression across reproductive age, using validated serum fibrosis markers, aminotransferase platelet ratio index (APRI) and fibrosis 4 (FIB-4). Fibrosis rate was evaluated within each woman as she transitioned from pre- to postmenopause, defined by a biomarker of ovarian function. Results. The median follow-up (n = 405) was 9.1 years (interquartile range, 5.0-15.2 years), with a median menopausal age of 49 years (47-52 years). When fully controlled for chronologic aging, the fibrosis progression rate was accelerated during perimenopause, as shown using FIB-4 (0.12 units per year faster than during premenopause; 95% confidence interval [CI], .02-.21; P = .01) and APRI (0.05 units per year faster; ?.002 to .09; P = .06). Accelerated fibrosis was also observed during postmenopause compared with premenopause, for FIB-4 (0.14 units per year faster; 95% CI, ?.01 to .29; P = .07) and APRI (0.07 units per year faster; ?.003 to .15; P = .06). Accelerated fibrosis in perimenopause persisted after adjustment for Hispanic ethnicity, antiretroviral use, and alcohol (0.10 FIB-4 units per year faster than during premenopause; 95% CI, .008-.20; P = .03). Conclusions. In HIV/HCV-coinfected women, hepatic fibrosis accelerates with reproductive aging. Accelerated fibrosis begins in perimenopause, highlighting a previously unrecognized group of women at increased risk for advanced fibrosis and associated complications. Longitudinal analyses of fibrosis rates across reproductive age should be conducted in non-HCV-related liver diseases, given potential implications in a broader spectrum of women.

AB - Background. Severity of hepatic fibrosis is greater in postmenopausal than in premenopausal women, perhaps owing to protective effects of estrogens. However, prior studies of estrogen and liver fibrosis lack serial fibrosis measures, adjustment for age, or longitudinal observations in coinfected populations. Methods. In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progression across reproductive age, using validated serum fibrosis markers, aminotransferase platelet ratio index (APRI) and fibrosis 4 (FIB-4). Fibrosis rate was evaluated within each woman as she transitioned from pre- to postmenopause, defined by a biomarker of ovarian function. Results. The median follow-up (n = 405) was 9.1 years (interquartile range, 5.0-15.2 years), with a median menopausal age of 49 years (47-52 years). When fully controlled for chronologic aging, the fibrosis progression rate was accelerated during perimenopause, as shown using FIB-4 (0.12 units per year faster than during premenopause; 95% confidence interval [CI], .02-.21; P = .01) and APRI (0.05 units per year faster; ?.002 to .09; P = .06). Accelerated fibrosis was also observed during postmenopause compared with premenopause, for FIB-4 (0.14 units per year faster; 95% CI, ?.01 to .29; P = .07) and APRI (0.07 units per year faster; ?.003 to .15; P = .06). Accelerated fibrosis in perimenopause persisted after adjustment for Hispanic ethnicity, antiretroviral use, and alcohol (0.10 FIB-4 units per year faster than during premenopause; 95% CI, .008-.20; P = .03). Conclusions. In HIV/HCV-coinfected women, hepatic fibrosis accelerates with reproductive aging. Accelerated fibrosis begins in perimenopause, highlighting a previously unrecognized group of women at increased risk for advanced fibrosis and associated complications. Longitudinal analyses of fibrosis rates across reproductive age should be conducted in non-HCV-related liver diseases, given potential implications in a broader spectrum of women.

KW - anti-mllerian hormone

KW - fibrosis markers

KW - hepatic scarring

KW - hormones

KW - menopause

UR - http://www.scopus.com/inward/record.url?scp=85032719085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032719085&partnerID=8YFLogxK

U2 - 10.1093/cid/cix643

DO - 10.1093/cid/cix643

M3 - Article

C2 - 29020239

AN - SCOPUS:85032719085

VL - 65

SP - 1695

EP - 1702

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -